FMW Media’s New to The Street TV, a nationally syndicated TV show,
announces episode #390 airing
tonight, Monday, September
26, 2022, at 10:30 PM PT on the Fox
Business Network.
New to The Street’s 390th
TV episode features the following Companies and their
representatives:
1). PetVivo Holdings, Inc.’s (NASDAQ: PETV)
(NASDAQ: PETVW) ($PETV) interview with John Lai, CEO &
President.
2). Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP)
($ACXP) interview with David Luci, President / CEO.
3). Sekur Private Data, Ltd.’s (OTCQX: SWISF)
(CSE: SKUR) (FRA: GDT0) interview with Mr. Alain Ghiai, CEO.
4). Phixey, Inc.’s interview with Alexandra
Poirier, Communications Manager.
Episode #390
Tonight, New to The Street TV is airing the Nasdaq
Marketplace studio interview with John Lai, CEO /
President PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV).
The Company is a biomedical device company that manufactures,
commercializes, and licenses innovative medical devices and
therapeutics for companion animals. Talking with TV Host Jane King,
John gives viewers an update on the recent launch of the
distribution agreement between PETV and MWI Animal Health (MWI), a
leading animal health products and services distributor, and
Amerisource Bergen subsidiary. With over $5B in annual revenue, MWI
is one of the largest distributors of veterinary drugs and
products, with lots of business resources and skilled personnel.
Securos is the educational division at MWI, which provides
hands-on training, resources, and continuing education for
veterinarians, helping them understand the full benefits of
products. The educational and sales/ market teams at MWI now
promote and distribute PETV’s injectable patented Spryng with
OsteoCushion Technology that treats osteoarthritis and joint
afflictions for dogs, horses, and cats. As a naturally derived
product, Spryng mimics collagen tissue that significantly improves
animals’ afflicted joints. The feline osteoarthritis version of
Spryng is coming to market soon. John says the Spryng roll-out with
MWI is going very well. He explains three reasons for Spryng
continued growth: 1) it is a naturally derived product, 2) it is
not a pharmaceutical or biological derived product, and 3) it has a
recyclable package in line with ESG (Environmental, Social, and
Governance) standards. Recently, PETV hired more seasoned personnel
with over two decades of sales/marketing experience in the pet
industry. The on-screen QR code is available during the show;
download or visit PetVivo Holdings, Inc. -
https://petvivo.com/ and Spryng with OsteoCushion Technology
- https://www.sprynghealth.com/.
On New to The Street TV tonight, David Luci, the
President / CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)
($ACXP), sits with TV Host Jane King from the Nasdaq Marketplace
studio. Acurx Pharmaceuticals, Inc. is a clinical biopharmaceutical
business, developing a new class of antibiotics for bacterial
infections. David discusses the Company's novel Ibezapolstat drug,
a potential treatment for Clostridioides difficile Infections (C.
difficile) (CDI). Treatments to combat CDI is a $1.7B year market.
With the recent positive outcome from Ibezapolstat's FDA Phase 2a
clinical and microbiome data, the Company is now enrolling patients
for its FDA Phase 2b trial. CDI kills about 29,000 people annually;
many catch the infection in hospitals and nursing homes. Clinical
data to date shows that Ibezapolstat increases the good microbiome
bacteria in the gut, and it demonstrated eradication of CDI during
3-days of treatment. David references Summit Therapeutics, and
their recent Phase 3 FDA failure on a competitive CDI drug. There
has been NO new class of antibiotic drugs since 1984, and the
current frontline treatment Vancomycin, has limitations with about
a 15-20% rate of CDI recurrence. Big Pharma wants a new class of
antibiotics to combat CDI and other bacterial infections. The
second drug in ACXP’s pipeline is ACX-375C, a potential drug to
overcome methicillin-resistant Staphylococcus aureus (MRSA)
infections. Disease data shows that MRSA accounts for 52% of US
hospital inpatient infections. Based on early scientific data,
ACXP’s management will proceed with all the FDA steps on AXX-375C
with the hope of become another useful drug. David explains that
being public is essential and helps the Company raise money, as
needed, going forward with current and other pipeline treatments.
David will do a follow-up interview to inform viewers of the
progress with the Ibezapolstat drug and the Company. The on-screen
QR code is available during the show; download or visit Acurx
Pharmaceticals, Inc. - https://www.acurxpharma.com/
Tonight, Mr. Alain Ghiai, CEO, Sekur Private
Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF)
(Sekur®), is with New to The Street’s TV Host Jane King. Viewers
receive an overview of the successful Q2 corporate financial
fundamentals based on selling its Sekur® cybersecurity products.
Alain told viewers that sales increased over 1100% for Q2 ending
June 30, 2022, compared to Q2, 2021. And the Q3 numbers look to
exceed that of Q2. The Company has good cash-on-hand of $4M, no
debt, and expects operational profitability sometime in 2023. With
increases in new subscribers, up 800% year-to-date, and the
existing subscribers purchasing more licenses, the revenue
expectations look to be around 200% higher in 2022 than in 2021.
Revenue growth continues to be strong, with only a small number of
subscribers canceling services. Sekur reduces marketing costs with
in-house SEO marketing personnel. The Company will no longer be
using 3rd party SEO entities. The financial matrix in Q2
successfully showed that Sekur’s SaaS (Software a as Service)
business model is working well with strong upward momentum. Alain
informs viewers that profitability is likely based on current
subscription rates and expected sales growth to continue throughout
2023. Sekur Private Date, Ltd. expects to announce three corporate
partnerships with a digital media company, an e-commerce entity,
and a B2B cyber platform that competes with Shopify. The 2023
profitability expectation does not account for the expected
subscription percentage increase that might come from these
partnerships. If only a 1/3 of the expectations subscribe from
these partners, operational profitability will come sooner than
expected in 2023. Alain expects to grow its small business
subscription base in 2023 with cost-efficient security products.
With the persistent and increased hacking of personal data and
privacy breaches on individuals and businesses, Sekur is getting
new subscribers for its email, text, and other encrypted platforms.
Viewers can learn more about the Company’s email, text, and
additional encrypted security platforms through video tutorials
posted on the Company’s website. Remember: Sekur operates its
internet platforms and security businesses under the country of
Switzerland’s very tough privacy laws. The on-screen QR code is
available during the show; download or visit Sekur Private Data,
Ltd. – https://www.sekurprivatedata.com/ and
http://www.Sekur.com.
Tonight from the Nasdaq Marketplace studio,
Alexandra Poirier, Communications Manager of Phixey, Inc. talks
with New to the Street’s TV Host Jane King about Phixey, Inc., an
electronics club that repairs devices and offers other membership
perks. The main membership benefit is a device fixed for “FREE.”
Like AAA for automobile members, Phixey offers its members benefits
and electronic service repair options on devices. In business for
15 years, Phixey is a disrupter in the electronic device repair
service industry, offering a membership fee as low as $19.95 per
year, $1.66 a month. The electronic service repair business is a
billion-dollar-a-year industry, and Phixey is the only entity in
the world that offers this type of electronic club membership. Cell
phone breakage happens often; the glass screen is fragile. Phixey
members get those screens repaired “FREE.” The current average cost
of cell phone repairs ranges from $150-$800. The only price to a
Phixey member is the yearly- fee. The club’s services are not part
of an insurance policy plan and have no deductibles. Cell phones,
laptops, computers, electronic wearables, and tablets can have a
membership, and each device has its owner membership to take
advantage of the club’s benefits. Another upcoming benefit is the
Phixey Wireless cell phone plan, unlimited talk and text for
$10.00, hosted on T-Mobile. Also, members get a discount on
accessories with free shipping or a 25% off at affiliate retailers.
Viewers who want to become members can join by going to the
website: https://phixey.com/Membership. Once a member and your
device become broken, you log back into the website and request
service, and Phixey provides a technician in your area. With over
2M members expected to be part of the Phixey Club, it expects to be
a household brand name with everyone. The Company is not public,
but it can accept direct investments. To learn more, send an email
to info@phixey.com with the title in email “Investment
Opportunity.” The on-screen QR code is available during the show;
download or visit Phixey, Inc. - https://phixey.com.
About PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW)
($PETV):
PetVivo Holdings Inc. (NASDAQ: PETV) (NASDAQ:
PETVW) ($PETV) is an emerging biomedical device company focused on
manufacturing, commercializing, and licensing innovative medical
devices and therapeutics for companion animals. The Company’s
strategy is to leverage human therapies for treating companion
animals cost-effectively and time-efficiently. A vital component of
this strategy is the accelerated timeline to revenues for
veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of
animals and people. A portfolio of nineteen patents protects the
Company’s biomaterials, products, production processes, and methods
of use. The Company’s lead product SPRYNG™ with
OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint-related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale -
https://petvivo.com/.
About Acurx Pharmaceuticals, Inc.
(NASDAQ: ACXP) ($ACXP):
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)
($ACXP) is a clinical-stage
biopharmaceutical Company focused on developing new
antibiotics for difficult-to-treat infections. The Company's
approach is to develop antibiotic candidates that target the DNA
polymerase IIIC enzyme. Its R&D pipeline includes antibiotic
product candidates that target Gram-positive bacteria, including
Clostridioides difficile, methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and
drug-resistant Streptococcus pneumoniae (DRSP). The Company’s
Ibezapolstat is a novel, orally administered antibiotic developed
as a Gram-Positive Selective Spectrum (GPSS™) antibacterial.
It is the first of a new class of DNA polymerase IIIC inhibitors
under development by Acurx to treat bacterial infections.
Ibezapolstat's unique spectrum of activity, which includes C.
difficile but spares other Firmicutes and the important
Actinobacteria phyla, appears to contribute to maintaining a
healthy gut microbiome. The Company completed Phase 1 and Phase 2a
clinical trials of ibezapolstat. To learn more about Acurx
Pharmaceuticals and its product pipeline, please
visit www.acurxpharma.com.
About Phixey,
Inc.:
Phixey, Inc., an electronic repair business for
over 15 years, helps customers with their cell phone, tablet, and
laptop service needs. The Company has agreements with DrPhoneFix,
Techy, Experimax, and InMotion, totaling about 300 stores
worldwide. Customers have no limits to where they can go to get
their electronic devices repaired. Device owners can have
peace of mind that their devices stay protected without high repair
costs, monthly premiums, and high deductibles. Phixey is simply a
club for cell phone, tablet, laptop, computer, and wearable owners
that gives you tremendous benefits. With Phixey, Inc., the days of
high repair costs, monthly premiums, and ridiculous deductibles are
out - https://phixey.com/.
About FMW Media:
FMW Media operates one of the longest-running US
and International sponsored and Syndicated Nielsen Rated
programming TV brands, “New to The Street,” and its blockchain
show, “Exploring The Block.” Since 2009, these brands have run
biographical interview segment shows across major U.S. Television
networks. The paid-for-TV programming platforms can potentially
reach over 540 million homes in the US and international markets.
FMW’s New to The Street / Newsmax TV broadcasting platform airs its
syndication on Sundays at 10 -11 AM ET. FMW is also one of the
nation’s largest buyers of linear television, long and short-form
paid programming
- https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.
Forward-Looking Statements
Disclaimer:
This press release contains forward-looking
statements within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934. In
some cases, you can identify forward-looking statements by the
following words: “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would,” or
the negative of these terms or other comparable terminology.
However, not all forward-looking statements contain these words.
Forward-looking statements are not a guarantee of future
performance or results and will not necessarily be accurate
indications of the times at which such performance or results are
achieved. This press release should be considered in all filings of
the Companies contained in the Edgar Archives of the Securities and
Exchange Commission at www.sec.gov.
CONTACT:
FMW Media Contacts:
Bryan Johnson +1 (631) 766-7462
Bryan@NewToTheStreet.com
“New to The Street” Business Development Office
1-516-696-5900 Support@NewToTheStreet.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1299b139-ab8e-47f4-9d82-5eccc5f109a4
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Mar 2024 to Apr 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Apr 2023 to Apr 2024